[Huahai Pharmaceutical: Net profit is expected to increase by 170%-190% year-on-year in the first three quarters of 2026] On October 7, Huahai Pharmaceutical (600521.SH) announced that the net profit attributable to shareholders of listed companies in the first three quarters of 2026 is expected to be 1.028 billion yuan-1.103 billion yuan, a year-on-year increase of 170%-190%. The changes in performance are mainly due to the significant increase in sales revenue of the API business, the expansion of the domestic preparation business' centralized procurement of winning products, the turnaround of the US preparation business, and the reduction in arbitration winnings and R&D expenses. Xiaocai's note: The company's Q3 net profit is expected to be 257 million to 332 million, and Q2 net profit is 367 million. Based on this calculation, Q3 net profit is expected to decrease by 9% to 29% month-on-month.